Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Public ClinicalTrials.gov record NCT01951638. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Study identification
- NCT ID
- NCT01951638
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 477 participants
Conditions and interventions
Conditions
Interventions
- Vericiguat (BAY1021189) (1.25 mg) Drug
- Vericiguat (BAY1021189) (5 mg) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2013
- Primary completion
- Aug 17, 2015
- Completion
- Sep 15, 2015
- Last update posted
- Mar 15, 2021
2013 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fountain Valley | California | 92708 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Naples | Florida | 34102 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Chicago | Illinois | 60611-2908 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | New Orleans | Louisiana | 70112-1396 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Minneapolis | Minnesota | 55422 | — |
| Not listed | Jackson | Mississippi | 39216-4505 | — |
| Not listed | Newark | New Jersey | 07103 | — |
| Not listed | Buffalo | New York | 14215 | — |
| Not listed | Pittsburgh | Pennsylvania | 15212 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Nashville | Tennessee | 37232-8802 | — |
| Not listed | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01951638, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2021 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01951638 live on ClinicalTrials.gov.